|Day Low/High||250.22 / 258.93|
|52 Wk Low/High||228.00 / 459.75|
In a letter sent to healthcare providers today, the U.S.
Abiomed (NASDAQ:ABMD) announces today that the Impella CP with SmartAssist, which is designed to improve patient outcomes with advanced algorithms and simplified patient management, will be commercially available beginning at the 2019 Society for...
The medical device maker rebounded from much bigger losses earlier in the day, however.
Abiomed (NASDAQ: ABMD) announces that, on April 26, the FDA approved initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial.
New research adds to 12 years of real-world data and FDA studies demonstrating the use of Abiomed's (NASDAQ: ABMD) Impella heart pumps during high-risk PCI (Protected PCI) enables skilled interventional cardiologists to achieve more complete...
Breadth looks like it did in late February as the McClellan Summation Index starts to roll over -- from a lower high.
Cramer says these red-hot and hopelessly overvalued IPOs are signs people are too bullish. Here's your game plan for next week.
Jim Cramer takes a closer look at Kraft Heinz, PepsiCo, Marvell Technology, General Mills, Funko, Signet Jewelers, Abiomed and more.
Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, May 2, 2019, the Company will release financial results for the fourth quarter of fiscal 2019.
Three years ago this week, Abiomed's (NASDAQ: ABMD) Impella heart pump received its FDA PMA approval for AMI cardiogenic shock.
The biggest IPO of the year so far is likely to set a trend, Jim Cramer says.
Abiomed (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies and the maker of the Impella RP heart pump, announces that survival data from the 18 month post-approval study of 42 Impella RP patients was presented at the American...
The hemodynamic support of Abiomed's (NASDAQ: ABMD) Impella heart pump platform for high-risk PCI and treatment of cardiogenic shock will be highlighted in more than 30 presentations and posters at the American College of Cardiology's (ACC) 68th Annual...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ABIOMED, Inc. , where a total of 1,651 contracts have traded so far, representing approximately 165,100 underlying shares.
In a milestone for scientific research, Abiomed (NASDAQ: ABMD) has now invested more than $100 million over the past five years in clinical research on the Impella heart pump platform.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ABIOMED, Inc. , where a total of 4,608 contracts have traded so far, representing approximately 460,800 underlying shares.
Abiomed (NASDAQ:ABMD) has achieved CE Mark for Impella Connect, the first-of-its kind cloud-based technology that enables secure, real-time, remote viewing of the Impella console for physicians and hospital staff from anywhere with Internet connectivity.
Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, January 31, 2019, the company will release financial results for the third quarter of fiscal 2019.
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R.
In the daily bar chart of Abiomed we can see a number of bearish signals.
Jim Cramer weighs in on Hormel, Medtronic, Cisco and more.
Jim Cramer says the market pain will eventually end, once the Fed sees the error of its ways.
Abiomed (NASDAQ: ABMD) announces the results of the FDA STEMI Door-to-Unloading safety and feasibility randomized controlled trial, which show unloading the left ventricle with Impella CP ® for 30 minutes prior to reperfusion in patients presenting with...
Jim Cramer is concerned about risk, and the Fed. But, he says, you need to get in there and talk with the CEOs to get the real story about the economy.
Jim Cramer takes a closer look at Express Scripts, Lockheed Martin, Raytheon, Abiomed.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.